John A Merenich

Summary

Affiliation: Kaiser Permanente
Country: USA

Publications

  1. ncbi Mortality reduction benefits of a comprehensive cardiac care program for patients with occlusive coronary artery disease
    John A Merenich
    Department of Endocrinology, Colorado Permanente Medical Group, Denver, Colorado, USA
    Pharmacotherapy 27:1370-8. 2007
  2. ncbi Clinical pharmacy specialist implementation of lisinopril therapy in patients with coronary artery disease and diabetes mellitus
    Karen J McConnell
    School of Pharmacy, University of Colorado Health Sciences Center, USA
    Pharmacotherapy 23:1564-72. 2003
  3. ncbi Factors associated with recurrent coronary events among patients with cardiovascular disease
    Karen J McConnell
    Clinical Pharmacy Cardiac Risk Service, Kaiser Permanente Colorado, Aurora, Colorado 80011, USA
    Pharmacotherapy 29:906-13. 2009
  4. ncbi Angiotensin-converting enzyme inhibitor therapy for coronary artery disease and diabetes mellitus
    Karen J McConnell
    Clinical Pharmacy Cardiac Risk Service, Kaiser Permanente of Colorado, Aurora, Colo 80011, USA
    Am J Manag Care 13:560-6. 2007
  5. ncbi Clinical pharmacy cardiac risk service for managing patients with coronary artery disease in a health maintenance organization
    Brian G Sandhoff
    Clinical Pharmacy Cardiac Risk Service, Kaiser Permanente of Colorado KPCO, Aurora, Colorado 80011, USA
    Am J Health Syst Pharm 64:77-84. 2007
  6. ncbi Coronary artery disease and hypertension: outcomes of a pharmacist-managed blood pressure program
    Karen J McConnell
    Clinical Pharmacy Cardiac Risk Service, Kaiser Permanente of Colorado, Aurora, Colorado 80011, USA
    Pharmacotherapy 26:1333-41. 2006
  7. ncbi Outcomes of patients discharged from pharmacy-managed cardiovascular disease management
    Kari L Olson
    Pharmacy Department, Kaiser Permanente Colorado, Aurora, CO 80011, USA
    Am J Manag Care 15:497-503. 2009
  8. ncbi Low myopathy rates associated with statins as monotherapy or combination therapy with interacting drugs in a group model health maintenance organization
    Roberta L Shanahan
    Anticoagulation and Cardiac Risk Service, Westminster Primary Care, Longmont, Colorado 80305, USA
    Pharmacotherapy 25:345-51. 2005
  9. ncbi Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization
    Kari L Olson
    Departments of Pharmacy, Clinical Pharmacy Cardiac Risk Service, Kaiser Permanente Colorado Region, Aurora, CO 80211, USA
    Arch Intern Med 165:49-54. 2005
  10. ncbi Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization
    Evguenia C Charles
    Clinical Pharmacy Cardiac Risk Service, Kaiser Permanente of Colorado, Denver, Colorado, USA
    Am J Med 118:618-24. 2005

Detail Information

Publications16

  1. ncbi Mortality reduction benefits of a comprehensive cardiac care program for patients with occlusive coronary artery disease
    John A Merenich
    Department of Endocrinology, Colorado Permanente Medical Group, Denver, Colorado, USA
    Pharmacotherapy 27:1370-8. 2007
    ..To determine the effect of early and sustained enrollment in a comprehensive cardiac care (CCC) program on all-cause mortality in patients with coronary artery disease (CAD)...
  2. ncbi Clinical pharmacy specialist implementation of lisinopril therapy in patients with coronary artery disease and diabetes mellitus
    Karen J McConnell
    School of Pharmacy, University of Colorado Health Sciences Center, USA
    Pharmacotherapy 23:1564-72. 2003
    ....
  3. ncbi Factors associated with recurrent coronary events among patients with cardiovascular disease
    Karen J McConnell
    Clinical Pharmacy Cardiac Risk Service, Kaiser Permanente Colorado, Aurora, Colorado 80011, USA
    Pharmacotherapy 29:906-13. 2009
    ..To determine which factors are associated with recurrent coronary events...
  4. ncbi Angiotensin-converting enzyme inhibitor therapy for coronary artery disease and diabetes mellitus
    Karen J McConnell
    Clinical Pharmacy Cardiac Risk Service, Kaiser Permanente of Colorado, Aurora, Colo 80011, USA
    Am J Manag Care 13:560-6. 2007
    ....
  5. ncbi Clinical pharmacy cardiac risk service for managing patients with coronary artery disease in a health maintenance organization
    Brian G Sandhoff
    Clinical Pharmacy Cardiac Risk Service, Kaiser Permanente of Colorado KPCO, Aurora, Colorado 80011, USA
    Am J Health Syst Pharm 64:77-84. 2007
    ..A clinical pharmacy service for managing the treatment of coronary artery disease in a health maintenance organization is described...
  6. ncbi Coronary artery disease and hypertension: outcomes of a pharmacist-managed blood pressure program
    Karen J McConnell
    Clinical Pharmacy Cardiac Risk Service, Kaiser Permanente of Colorado, Aurora, Colorado 80011, USA
    Pharmacotherapy 26:1333-41. 2006
    ..To assess the effectiveness of a pharmacist-managed service in improving hypertension control among patients with coronary artery disease...
  7. ncbi Outcomes of patients discharged from pharmacy-managed cardiovascular disease management
    Kari L Olson
    Pharmacy Department, Kaiser Permanente Colorado, Aurora, CO 80011, USA
    Am J Manag Care 15:497-503. 2009
    ..To evaluate whether patients with coronary artery disease (CAD) discharged from the Clinical Pharmacy Cardiac Risk Service (CPCRS) would maintain their lipid goals with use of an electronic laboratory reminder system...
  8. ncbi Low myopathy rates associated with statins as monotherapy or combination therapy with interacting drugs in a group model health maintenance organization
    Roberta L Shanahan
    Anticoagulation and Cardiac Risk Service, Westminster Primary Care, Longmont, Colorado 80305, USA
    Pharmacotherapy 25:345-51. 2005
    ....
  9. ncbi Lipid management in patients with coronary artery disease by a clinical pharmacy service in a group model health maintenance organization
    Kari L Olson
    Departments of Pharmacy, Clinical Pharmacy Cardiac Risk Service, Kaiser Permanente Colorado Region, Aurora, CO 80211, USA
    Arch Intern Med 165:49-54. 2005
    ..The aim of this study is to examine the impact of a clinical pharmacy cardiac risk service (CPCRS) on lipid screening, control, and treatment outcomes...
  10. ncbi Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization
    Evguenia C Charles
    Clinical Pharmacy Cardiac Risk Service, Kaiser Permanente of Colorado, Denver, Colorado, USA
    Am J Med 118:618-24. 2005
    ..These findings support less frequent liver enzyme monitoring for most patients on statins. Continued monitoring remains warranted for patients on concomitant medications or those with comorbid conditions...
  11. ncbi Atherosclerotic risk factor control in patients with peripheral arterial disease
    Thomas F Rehring
    Department of Vascular Surgery, Colorado Permanente Medical Group, Denver, CO 80205, USA
    J Vasc Surg 41:816-22. 2005
    ..The purpose of this study was to determine the status of atherosclerotic risk factor control in patients with PAD...
  12. ncbi Attendance and graduation patterns in a group-model health maintenance organization alternative cardiac rehabilitation program
    Andria M Ratchford
    University of Colorado Health Sciences Center, Denver, USA
    J Cardiopulm Rehabil 24:150-6. 2004
    ..This study evaluated the participation rates for the program and the predictors of attendance and graduation...
  13. ncbi Effect of a clinical pharmacy service on lipid control in patients with peripheral arterial disease
    Thomas F Rehring
    Department of Vascular Surgery, Colorado Permanente Medical Group, University of Colorado Health Sciences Center, Denver, CO 80205, USA
    J Vasc Surg 43:1205-10. 2006
    ..The purpose of this study was to determine the effect of this service on lipid screening and control in patients with PAD...
  14. ncbi The Long-term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization
    Julie A Porter
    Aventis Pharmaceuticals, Inc, Bridgewater, NJ 08807, USA
    Am J Manag Care 10:369-76. 2004
    ..To assess the benefit of sibutramine hydrochloride monohydrate within a weight management program...
  15. ncbi Cost-effectiveness of sibutramine in the LOSE Weight Study: evaluating the role of pharmacologic weight-loss therapy within a weight management program
    Daniel C Malone
    University of Arizona College of Pharmacy, PO Box 210207, Tucson, AZ 85721, USA
    J Manag Care Pharm 11:458-68. 2005
    ..The core WMP was a physician-supervised, multidisciplinary program for which each enrollee paid $100 out of pocket...
  16. ncbi The triglyceride-lowering effects of a modest dose of docosahexaenoic acid alone versus in combination with low dose eicosapentaenoic acid in patients with coronary artery disease and elevated triglycerides
    Lisa J Schwellenbach
    Kaiser Permanente Colorado, Clinical Pharmacy Cardiac Risk Service, Aurora, CO 80011, USA
    J Am Coll Nutr 25:480-5. 2006
    ..There do not appear to be significant differences in triglyceride-lowering between DHA only and DHA + EPA combination products when dosing is based on DHA...